Report Detail
Global (United States, European Union and China) Anti-epileptic Drugs for Pediatrics Market Research Report 2019-2025
- RnM3578826 |
- 08 July, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
In 2019, the market size of Anti-epileptic Drugs for Pediatrics is 830 million US$ and it will reach 1530 million US$ in 2025, growing at a CAGR of 7.9% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anti-epileptic Drugs for Pediatrics.
This report studies the global market size of Anti-epileptic Drugs for Pediatrics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Anti-epileptic Drugs for Pediatrics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Market Segment by Product Type
1st generation
2nd generation
3rd generation
Market Segment by Application
Hospitals
Retail pharmacies
Online pharmacies
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Anti-epileptic Drugs for Pediatrics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Anti-epileptic Drugs for Pediatrics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Anti-epileptic Drugs for Pediatrics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 1st generation
- 1.3.3 2nd generation
- 1.3.4 3rd generation
- 1.4 Market Segment by Application
- 1.4.1 Global Anti-epileptic Drugs for Pediatrics Market Share by Application (2019-2025)
- 1.4.2 Hospitals
- 1.4.3 Retail pharmacies
- 1.4.4 Online pharmacies
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Anti-epileptic Drugs for Pediatrics Market Size
- 2.1.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2014-2025
- 2.1.2 Global Anti-epileptic Drugs for Pediatrics Sales 2014-2025
- 2.2 Anti-epileptic Drugs for Pediatrics Growth Rate by Regions
- 2.2.1 Global Anti-epileptic Drugs for Pediatrics Sales by Regions 2014-2019
- 2.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers
- 3.1.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers 2014-2019
- 3.1.2 Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Anti-epileptic Drugs for Pediatrics Market Concentration Ratio (CR5 and HHI)
- 3.3 Anti-epileptic Drugs for Pediatrics Price by Manufacturers
- 3.4 Key Manufacturers Anti-epileptic Drugs for Pediatrics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market
- 3.6 Key Manufacturers Anti-epileptic Drugs for Pediatrics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 1st generation Sales and Revenue (2014-2019)
- 4.1.2 2nd generation Sales and Revenue (2014-2019)
- 4.1.3 3rd generation Sales and Revenue (2014-2019)
- 4.2 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type
- 4.3 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type
- 4.4 Anti-epileptic Drugs for Pediatrics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Anti-epileptic Drugs for Pediatrics Sales by Application
6 United States
- 6.1 United States Anti-epileptic Drugs for Pediatrics Breakdown Data by Company
- 6.2 United States Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
- 6.3 United States Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
7 European Union
- 7.1 European Union Anti-epileptic Drugs for Pediatrics Breakdown Data by Company
- 7.2 European Union Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
- 7.3 European Union Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
8 China
- 8.1 China Anti-epileptic Drugs for Pediatrics Breakdown Data by Company
- 8.2 China Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
- 8.3 China Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Anti-epileptic Drugs for Pediatrics Breakdown Data by Company
- 9.2 Rest of World Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
- 9.3 Rest of World Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
- 9.4 Rest of World Anti-epileptic Drugs for Pediatrics Breakdown Data by Countries
- 9.4.1 Rest of World Anti-epileptic Drugs for Pediatrics Sales by Countries
- 9.4.2 Rest of World Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Mylan N.V
- 10.1.1 Mylan N.V Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.1.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.1.5 Mylan N.V Recent Development
- 10.2 Cephalon, Inc
- 10.2.1 Cephalon, Inc Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.2.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.2.5 Cephalon, Inc Recent Development
- 10.3 GlaxoSmithKline plc
- 10.3.1 GlaxoSmithKline plc Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.3.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.3.5 GlaxoSmithKline plc Recent Development
- 10.4 Janssen Pharmaceuticals
- 10.4.1 Janssen Pharmaceuticals Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.4.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.4.5 Janssen Pharmaceuticals Recent Development
- 10.5 Novartis AG
- 10.5.1 Novartis AG Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.5.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.5.5 Novartis AG Recent Development
- 10.6 Pfizer, Inc
- 10.6.1 Pfizer, Inc Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.6.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.6.5 Pfizer, Inc Recent Development
- 10.7 Sanofi S.A
- 10.7.1 Sanofi S.A Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.7.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.7.5 Sanofi S.A Recent Development
- 10.8 UCB Pharma Limited
- 10.8.1 UCB Pharma Limited Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.8.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.8.5 UCB Pharma Limited Recent Development
- 10.9 Sunovion Pharmaceuticals Limited
- 10.9.1 Sunovion Pharmaceuticals Limited Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.9.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.9.5 Sunovion Pharmaceuticals Limited Recent Development
- 10.10 Valeant Pharmaceuticals International, Inc
- 10.10.1 Valeant Pharmaceuticals International, Inc Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Anti-epileptic Drugs for Pediatrics
- 10.10.4 Anti-epileptic Drugs for Pediatrics Product Introduction
- 10.10.5 Valeant Pharmaceuticals International, Inc Recent Development
- 10.11 Zogenix
- 10.12 GW Pharmaceuticals
- 10.13 Insys
- 10.14 Zynerba
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Anti-epileptic Drugs for Pediatrics Sales Channels
- 11.2.2 Anti-epileptic Drugs for Pediatrics Distributors
- 11.3 Anti-epileptic Drugs for Pediatrics Customers
12 Market Forecast
- 12.1 Global Anti-epileptic Drugs for Pediatrics Sales and Revenue Forecast 2019-2025
- 12.2 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type
- 12.3 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application
- 12.4 Anti-epileptic Drugs for Pediatrics Forecast by Regions
- 12.4.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Anti-epileptic Drugs for Pediatrics. Industry analysis & Market Report on Anti-epileptic Drugs for Pediatrics is a syndicated market report, published as Global (United States, European Union and China) Anti-epileptic Drugs for Pediatrics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Anti-epileptic Drugs for Pediatrics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
